BioAge Labs Reports Significant Results from BGE-102 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
BioAge Labs reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly announced 60 mg once-daily cohort dosed for 21 days in participants with obesity and elevated inflammation, demonstrates that BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein and consistent reductions across multiple inflammatory biomarkers, with a favorable tolerability profile. Notably, the 60 mg dose achieved hsCRP and other biomarker reductions comparable to the previously reported 120 mg dose. Based on the full Phase 1 dataset, BioAge intends to initiate a dose-ranging Phase 2 cardiovascular risk proof-of-concept trial in the first half of 2026, with data anticipated in the second half of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIOA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIOA
Wall Street analysts forecast BIOA stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 16.950
Low
15.00
Averages
37.00
High
73.00
Current: 16.950
Low
15.00
Averages
37.00
High
73.00
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: At the Annual General Meeting on May 28, 2026, BioArctic AB adopted its financial statements and declared a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to bolster shareholder confidence and attract further investment.
- Board Member Elections: The meeting re-elected Eugen Steiner as chairperson and appointed Philip Scheltens and Linda Nilsson as new board members, ensuring a blend of continuity and fresh perspectives that will aid in executing the company's strategic initiatives and innovations.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units to be awarded, aimed at motivating employees to enhance performance and drive long-term growth and competitiveness in the market.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor, ensuring financial transparency and compliance, which is expected to enhance investor trust in the company's financial health.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: BioArctic AB held its Annual General Meeting in Stockholm, adopting the income statement and balance sheet for FY 2025, and declaring a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to enhance shareholder confidence and improve the company's image.
- Board Member Elections: The meeting re-elected six board members including Eugen Steiner and appointed Philip Scheltens and Linda Nilsson, ensuring stability and continuity in corporate governance as all members serve until the next AGM.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units, designed to motivate employees to achieve a 30% total shareholder return, thereby driving long-term growth for the company.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor until the next AGM, ensuring financial transparency and compliance, which will help bolster investor trust in the company.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
BioArctic and Eisai Release Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi's sales are expected to reach approximately JPY 300 billion (around SEK 17.6 billion) for the fiscal year 2028, highlighting the drug's significant market potential and the prospect of substantial revenue growth for BioArctic.
- Global Market Approvals: Leqembi has been approved in 53 countries and is under regulatory review in 6 countries, demonstrating its broad acceptance in the global market and further solidifying BioArctic's leadership position in Alzheimer's disease treatment.
- Clinical Research Progress: Eisai's ongoing AHEAD 3-45 clinical study aims to evaluate the efficacy of lecanemab in early Alzheimer's disease patients, which is expected to provide crucial data for future market promotion and enhance BioArctic's competitive edge.
- Strategic Partnership: The long-term collaboration between BioArctic and Eisai since 2005 has positioned BioArctic advantageously in the development of Alzheimer's drugs, as it incurs no development costs and can earn milestone payments and royalties from global sales, ensuring financial stability.
See More
BioArctic and Eisai Present Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi is expected to generate around JPY 300 billion (approximately SEK 17.6 billion) in sales for FY 2028, highlighting the drug's significant potential in the Alzheimer's market and likely boosting BioArctic's revenue.
- Global Approval Status: Leqembi has been approved in 53 countries and is under regulatory review in 6 others, demonstrating broad global recognition, while BioArctic's preparations for commercialization in the Nordics will further enhance its market position.
- Clinical Research Progress: Eisai's AHEAD 3-45 clinical study was fully recruited in October 2024, aiming to assess the efficacy of lecanemab in early Alzheimer's patients, with successful results providing strong support for future market promotion.
- Strategic Partnership: Since 2005, BioArctic's long-term collaboration with Eisai has positioned it prominently in the Alzheimer's treatment field, allowing BioArctic to avoid development costs while securing milestone payments and royalties from global sales, ensuring financial stability.
See More
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: At the Annual General Meeting on May 28, 2026, BioArctic AB adopted its financial statements and declared a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to bolster shareholder confidence and attract further investment.
- Board Member Elections: The meeting re-elected Eugen Steiner as chairperson and appointed Philip Scheltens and Linda Nilsson as new board members, ensuring a blend of continuity and fresh perspectives that will aid in executing the company's strategic initiatives and innovations.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units to be awarded, aimed at motivating employees to enhance performance and drive long-term growth and competitiveness in the market.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor, ensuring financial transparency and compliance, which is expected to enhance investor trust in the company's financial health.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: BioArctic AB held its Annual General Meeting in Stockholm, adopting the income statement and balance sheet for FY 2025, and declaring a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to enhance shareholder confidence and improve the company's image.
- Board Member Elections: The meeting re-elected six board members including Eugen Steiner and appointed Philip Scheltens and Linda Nilsson, ensuring stability and continuity in corporate governance as all members serve until the next AGM.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units, designed to motivate employees to achieve a 30% total shareholder return, thereby driving long-term growth for the company.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor until the next AGM, ensuring financial transparency and compliance, which will help bolster investor trust in the company.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
BioArctic and Eisai Release Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi's sales are expected to reach approximately JPY 300 billion (around SEK 17.6 billion) for the fiscal year 2028, highlighting the drug's significant market potential and the prospect of substantial revenue growth for BioArctic.
- Global Market Approvals: Leqembi has been approved in 53 countries and is under regulatory review in 6 countries, demonstrating its broad acceptance in the global market and further solidifying BioArctic's leadership position in Alzheimer's disease treatment.
- Clinical Research Progress: Eisai's ongoing AHEAD 3-45 clinical study aims to evaluate the efficacy of lecanemab in early Alzheimer's disease patients, which is expected to provide crucial data for future market promotion and enhance BioArctic's competitive edge.
- Strategic Partnership: The long-term collaboration between BioArctic and Eisai since 2005 has positioned BioArctic advantageously in the development of Alzheimer's drugs, as it incurs no development costs and can earn milestone payments and royalties from global sales, ensuring financial stability.
See More
BioArctic and Eisai Present Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi is expected to generate around JPY 300 billion (approximately SEK 17.6 billion) in sales for FY 2028, highlighting the drug's significant potential in the Alzheimer's market and likely boosting BioArctic's revenue.
- Global Approval Status: Leqembi has been approved in 53 countries and is under regulatory review in 6 others, demonstrating broad global recognition, while BioArctic's preparations for commercialization in the Nordics will further enhance its market position.
- Clinical Research Progress: Eisai's AHEAD 3-45 clinical study was fully recruited in October 2024, aiming to assess the efficacy of lecanemab in early Alzheimer's patients, with successful results providing strong support for future market promotion.
- Strategic Partnership: Since 2005, BioArctic's long-term collaboration with Eisai has positioned it prominently in the Alzheimer's treatment field, allowing BioArctic to avoid development costs while securing milestone payments and royalties from global sales, ensuring financial stability.
See More
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
